FDA Sets Sights on Animal Testing; AI Privacy Threat; Chewing Gum for Cancer?

The FDA issued draft guidance aimed at reducing unnecessary use of animal testing for cancer drugs.

Former U.S. Attorney General Pam Bondi, 60, acknowledged that she has thyroid cancer. (People)

Work requirements for Medicaid beneficiaries could lead to a dramatic increase in missed cancer screenings. (UChicago Medicine)

A test for circulating tumor DNA identified patients at risk of breast cancer recurrence more than a year before the relapse became apparent by conventional testing methods. (Lund University)

Growing use of artificial intelligence (AI) in radiology may pose new threats to patient privacy. (Radiological Society of North America)

In an open letter to HHS Secretary Robert F. Kennedy Jr., 60 organizations representing cancer patients and survivors called for protections to maintain the integrity of the U.S. Preventive Services Task Force after the Trump administration dismissed its key leaders. (American Cancer Society)

The Oncology Institute, which owns and operates 100 cancer clinics in five states, acknowledged a cybersecurity breach involving patient data accessed by an unauthorized third party. (The HIPAA Journal)

Does bioengineered chewing gum have a role in preventing head and neck cancers? (WHYY)

Who got it right on the oral breast cancer drug camizestrant? The FDA, whose Oncologic Drugs Advisory Committee gave it a thumbs down, or the European Medicines Agency’s Committee for Medicinal Products for Human Use, which recommended approval? (Clinical Trial Vanguard)

Meanwhile, AstraZeneca said the FDA has decided to delay making a decision on camizestrant, pending a review of additional data.

Please enable JavaScript to view the comments powered by Disqus.